image
Healthcare - Medical - Devices - NASDAQ - US
$ 14.2
-1.59 %
$ 575 M
Market Cap
-20.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one RXST stock under the worst case scenario is HIDDEN Compared to the current market price of 14.2 USD, RxSight, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one RXST stock under the base case scenario is HIDDEN Compared to the current market price of 14.2 USD, RxSight, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one RXST stock under the best case scenario is HIDDEN Compared to the current market price of 14.2 USD, RxSight, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RXST

image
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
140 M REVENUE
57.09%
-36.9 M OPERATING INCOME
26.41%
-27.5 M NET INCOME
100.00%
-16.9 M OPERATING CASH FLOW
59.26%
-99.3 M INVESTING CASH FLOW
-348.78%
123 M FINANCING CASH FLOW
100.44%
40.2 M REVENUE
-11.44%
-8.63 M OPERATING INCOME
6.48%
-5.94 M NET INCOME
6.31%
-4.26 M OPERATING CASH FLOW
-655.38%
1.32 M INVESTING CASH FLOW
114.25%
2.98 M FINANCING CASH FLOW
238.95%
Balance Sheet RxSight, Inc.
image
Current Assets 294 M
Cash & Short-Term Investments 237 M
Receivables 30 M
Other Current Assets 26.6 M
Non-Current Assets 24.7 M
Long-Term Investments 0
PP&E 23.6 M
Other Non-Current Assets 1.11 M
74.47 %9.43 %8.33 %7.42 %Total Assets$318.6m
Current Liabilities 25.9 M
Accounts Payable 4.54 M
Short-Term Debt 974 K
Other Current Liabilities 20.4 M
Non-Current Liabilities 11.4 M
Long-Term Debt 11.3 M
Other Non-Current Liabilities 127 K
12.17 %54.54 %30.33 %Total Liabilities$37.3m
EFFICIENCY
Earnings Waterfall RxSight, Inc.
image
Revenue 140 M
Cost Of Revenue 41 M
Gross Profit 98.9 M
Operating Expenses 136 M
Operating Income -36.9 M
Other Expenses -9.4 M
Net Income -27.5 M
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)140m(41m)99m(136m)(37m)9m(27m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.71% GROSS MARGIN
70.71%
-26.34% OPERATING MARGIN
-26.34%
-19.62% NET MARGIN
-19.62%
-9.76% ROE
-9.76%
-8.62% ROA
-8.62%
-12.57% ROIC
-12.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis RxSight, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)202020202021202120222022202320232024202420252025
Net Income -27.5 M
Depreciation & Amortization 3.62 M
Capital Expenditures -5.44 M
Stock-Based Compensation 0
Change in Working Capital -9.21 M
Others -16.9 M
Free Cash Flow -22.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets RxSight, Inc.
image
Wall Street analysts predict an average 1-year price target for RXST of $69.6 , with forecasts ranging from a low of $52 to a high of $110 .
RXST Lowest Price Target Wall Street Target
52 USD 266.20%
RXST Average Price Target Wall Street Target
69.6 USD 390.44%
RXST Highest Price Target Wall Street Target
110 USD 674.65%
Price
Max Price Target
Min Price Target
Average Price Target
110110100100909080807070606050504040303020201010Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership RxSight, Inc.
image
Sold
0-3 MONTHS
180 K USD 1
3-6 MONTHS
1.62 M USD 2
6-9 MONTHS
3.42 M USD 2
9-12 MONTHS
4.92 M USD 3
Bought
0 USD 0
0-3 MONTHS
1.11 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
305 K USD 1
9-12 MONTHS
7. News
RxSight price target lowered to $17 from $22 at Wells Fargo Wells Fargo lowered the firm's price target on RxSight to $17 from $22 and keeps an Equal Weight rating on the shares following the conference call to discuss the preliminary Q1 2025 sales results and lowered FY25 guidance. The company called out weak LAL volume trends through Q1, especially March, competitive product launches, and recessionary concerns, Wells notes. 09 May https://thefly.com - 3 weeks ago
​RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was premature. The competitive landscape has intensified with new IOL products from Johnson & Johnson and Rayner, challenging RxSight's unique LAL technology. seekingalpha.com - 4 weeks ago
RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript) RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Preliminary Results Conference Call April 3, 2025 8:00 AM ET Company Participants Oliver Moravcevic - VP, IR Dr. Ron Kurtz - Director, Co-President and CEO Shelley Thunen - Assistant Secretary, Co-President and CFO Conference Call Participants Ryan Zimmerman - BTIG Xuyang Li - Jefferies Robert Marcus - JPMorgan Steve Lichtman - Oppenheimer David Saxon - Needham Danielle Antalffy - UBS Operator Thank you for standing by, and welcome to the RxSight conference call. All lines have been placed on mute to prevent any background noise. seekingalpha.com - 4 weeks ago
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. globenewswire.com - 1 month ago
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. globenewswire.com - 1 month ago
RxSight, Inc. (RXST) Q4 2024 Earnings Call Transcript RxSight, Inc. (NASDAQ:RXST ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Oliver Moravcevic - VP, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference Call Participants Lily Lozada - JPMorgan Ryan Zimmerman - BTIG Steve Lichtman - Oppenheimer David Saxon - Needham Lei Huang - Wells Fargo Danielle Antalffy - UBS Thomas Stephan - Stifel Operator Ladies and gentlemen, thank you for standing by. My name is Nasrin and I will be your conference operator today. seekingalpha.com - 2 months ago
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates RxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago. zacks.com - 2 months ago
RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024. globenewswire.com - 2 months ago
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. globenewswire.com - 3 months ago
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. globenewswire.com - 3 months ago
RxSight downgraded to Hold from Buy at Stifel Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL - intraocular lens - competition may be more material than investors appreciate, with JNJ's (JNJ) new Tecnis Odyssey lens "jumping off the page" in its findings and with Alcon's (ALC) PanOptix Pro around the corner, the analyst tells investors in a research note. Stifel adds that its longitudinal analysis shows the respondents' 2025 LAL - light adjustable lenses - volume expectations are moderately weakening, giving the firm pause around the intermediate-term LAL path ahead. RxSight +1.02 (+2.74%) Johnson & Johnson -1.16 (-0.80%) Alcon -0.56 (-0.66%) https://thefly.com - 4 months ago
Needham ups Alcon target, adds to Conviction List Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST). Alcon's product launch lineup is one of the best it's been since its spin from Novartis, the analyst told investors in a research note. Needham expects the product launches to result in Alcon's revenue growth accelerating throughout 2025, which should drive multiple expansion. The firm made the stock a top pick for 2025. With the stock's valuation meaningfully below Alcon's historical range, risks around currency and commercial investments are baked in, making the risk/reward attractive, contended Needham. Alcon +1.88 (+2.24%) RxSight -0.1 (-0.26%) https://thefly.com - 4 months ago
8. Profile Summary

RxSight, Inc. RXST

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 575 M
Dividend Yield 0.00%
Description RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Contact 100 Columbia, Aliso Viejo, CA, 92656 https://www.rxsight.com
IPO Date July 30, 2021
Employees 498
Officers Mr. Oliver Moravcevic Vice President of Investor Relations Dr. Ilya Goldshleger Ph.D. Co-President & Chief Operating Officer Ms. Shelley B. Thunen Co-President & Chief Financial Officer Ms. Caroline Vaughn Vice President of Human Resources Mr. Roy Freeman Senior Vice President of Marketing & Professional Relations Dr. Ronald M. Kurtz M.D. Co-President, Chief Executive Officer & Director Mr. Matt Haller Ph.D. Chief Technology Officer Mr. Eric J. Weinberg Co-President & Chief Commercial Officer Ms. Rebecca Williston Vice President of Accounting & Finance Mr. Steve Everly Senior Vice President of Sales of North America